Enveric Biosciences (ENVB) Notes Payables (2015 - 2023)

Enveric Biosciences (ENVB) posted Notes Payables of $714000.0 for Q1 2023, down 1.79% sequentially from $727000.0 in Q4 2022.

Enveric Biosciences (ENVB) Notes Payables (2015 - 2023) Analysis & Trends

Enveric Biosciences has reported Notes Payables for 7 years, with the latest figure at $714000.0 in Q1 2023.

Quarterly Notes Payables changed N/A year-over-year to $714000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $714000.0 (changed N/A YoY) and the FY2022 annual result came in at $727000.0, changed N/A from the prior year.
Notes Payables slipped to $714000.0 in Q1 2023 per ENVB's latest filing, from $727000.0 in the prior quarter.
Over five years, Notes Payables peaked at $1.0 million in Q1 2019 and troughed at $293921.0 in Q4 2019.
A 4-year average of $763991.2 and a median of $727000.0 in 2022 frame the typical range for Notes Payables.
The sharpest annual moves came in 2019 and 2020: Notes Payables plunged 76.49% in 2019, then changed 0.0% in 2020.
Over 4 years, Notes Payables stood at $293921.0 in 2019, then soared by 240.23% to $1.0 million in 2020, then declined by 27.3% to $727000.0 in 2022, then fell by 1.79% to $714000.0 in 2023.
According to Business Quant data, Notes Payables over the past three periods registered $714000.0, $727000.0, and $686000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Enveric Biosciences	5.66 Mn	-2.64 Mn	-

Download Data